Hepregen Corporation has announced the commercial launch of the Company's first application-oriented Rat HepatoPac™ kits designed specifically for use in metabolite identification and profiling.
A kit may be ordered that contains either Wistar-Hahn or Sprague-Dawley rat hepatocytes. Much like the recently introduced Hepregen Human HepatoPac™ kit, each of the kits provides customers with a plug-in-ready product, which includes live rat liver cells on a micro-patterned, standard 24-well tissue culture plate that remain fully functional for more than two months.
Data generated by the kits accurately predict the profile of drug metabolite generation in a species that is one of the most important in preclinical drug testing.
Moreover, when used in combination with its human liver cell counterpart early in the drug development process, the Human and Rat kits together provide data that helps select the best compounds to advance to pharmaceutical candidate status, mitigating development risks and lowering costs.
Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The launch of these application-specific kits provides our customers and preclinical CRO partners with a second fully validated option for accurately predicting the metabolic fate of candidate drugs and for evaluating the drug potential of predecessor compounds at all stages of product development. Using our rat and human kits together, drug developers can now evaluate how animal and human data will compare, increasing their confidence in the design of preclinical experiments and improving the efficiency of the drug development process."